Figure 4. The effects of in vivo administration of A366 on osteogenic potential of BM-MSCs. (A) Alizarin red staining of BM-MSC-derived osteocytes. The osteogenic potential of the BM-MSC isolated from A366-treated rats clearly is lower than control at P1, whereas it is almost similar at P2; (B, left) Absorbance-based quantification of Alizarin Red staining showed that in vivo administration of A366 reduced the amount of extracellular matrix deposition by osteocytes differentiated from P1/BM-MSCs; (B, right) ALP activity was significantly lower in osteocytes differentiated from P1/BM-MSC that were isolated from A366-treated rats; (C) the gene expression analysis of osteocytes differentiated from BM-MSCs. a': P < 0.05 vs a. Data are expressed as means ± SD. Runx2: Runt-related transcription factor 2, OCN: Osteocalcin, ALP: alkaline phosphatase, OSX: Osterix and Col1a1: Collagen Type I Alpha 1 Chain.